JP Morgan Chase
TERN

JP Morgan Chase’s Terns Pharmaceuticals TERN Stock Holding History

JP Morgan Chase’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-115,800
Closed -$966K – 7725
2024
Q3 		$966K Buy
+115,800
New +$953K ﹤0.01% 4487

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

JP Morgan Chase's TERN Position: Q1 2026 in Review

JP Morgan Chase increased its Terns Pharmaceuticals (TERN) stake by 62% in Q1 2026, buying an estimated $45M and bringing the position to 2,869,728 shares worth $152M. The position accounts for 0.01% of the portfolio, ranked #803.

JP Morgan Chase first reported a position in TERN in Q1 2021 and has held it in 21 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • JP Morgan Chase held 2,869,728 shares of Terns Pharmaceuticals worth $152M as of Q1 2026.
  • JP Morgan Chase bought 1,096,702 Terns Pharmaceuticals shares in Q1 2026, an estimated $45M.
  • Terns Pharmaceuticals made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #803 holding.
  • JP Morgan Chase first reported a position in Terns Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.